Literature DB >> 31728906

A Brazilian multicentre study evaluating pregnancies induced by cabergoline in patients harboring prolactinomas.

B G Sant' Anna1, N R C Musolino2, M R Gadelha3, C Marques3, M Castro4, P C L Elias4, L Vilar5, R Lyra5, M R A Martins6, A R P Quidute6, J Abucham7, D Nazato7, H M Garmes8, M L C Fontana8, C L Boguszewski9, C B Bueno10, M A Czepielewski11, E S Portes12, V S Nunes-Nogueira13, A Ribeiro-Oliveira14, R P V Francisco15, M D Bronstein16, A Glezer16.   

Abstract

OBJECTIVE: To evaluate the maternal-fetal outcomes of CAB-induced pregnancies in patients with prolactinoma in a large cohort.
METHODS: The prevalence of tumor growth, miscarriage, preterm, low birth weight, congenital malformations and impairment in neuropsychological development in children among women treated with CAB were assessed in a Brazilian multicentre retrospective observational study,
RESULTS: We included 194 women with a mean age of 31 (17-45) years, 43.6% presenting microadenomas and 56.4% macroadenomas, at prolactinoma diagnosis. In 233 pregnancies, CAB was withdrawn in 89%, after pregnancy confirmation. Symptoms related to tumor growth occurred in 25 cases, more frequently in macroadenomas. The overall miscarriage rate was 11%, although higher in the subgroup of patients with CAB maintainance after pregnancy confirmation (38% vs. 7.5%). Amongst the live-birth deliveries, preterm occurred in 12%, low birth weight in 6% and congenital malformations in 4.3%. Neuropsychological development impairment was reported in 7% of cases.
CONCLUSIONS: Our findings confirm previous results of safety in maternal and fetal outcomes in CAB-induced pregnancies; nevertheless, CAB maintenance after pregnancy confirmation was associated with higher miscarriage rate; result that must be further confirmed.

Entities:  

Keywords:  Cabergoline; Dopamine agonist; Malformation; Miscarriage; Pregnancy; Prolactinoma

Mesh:

Substances:

Year:  2020        PMID: 31728906     DOI: 10.1007/s11102-019-01008-z

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  58 in total

Review 1.  Medical management of prolactin-secreting pituitary adenomas.

Authors:  Mark E Molitch
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

2.  Management of prolactinomas during pregnancy.

Authors:  M E Molitch
Journal:  J Reprod Med       Date:  1999-12       Impact factor: 0.142

3.  Pregnancy outcome in women exposed to dopamine agonists during pregnancy: a pharmacoepidemiology study in EFEMERIS database.

Authors:  Caroline Hurault-Delarue; Jean-Louis Montastruc; Anna-Belle Beau; Isabelle Lacroix; Christine Damase-Michel
Journal:  Arch Gynecol Obstet       Date:  2014-03-25       Impact factor: 2.344

4.  Pregnancy and tumor outcomes in infertile women with macroprolactinoma on cabergoline therapy.

Authors:  Ashu Rastogi; Sanjay K Bhadada; Anil Bhansali
Journal:  Gynecol Endocrinol       Date:  2016-12-02       Impact factor: 2.260

5.  The Robson ten-group classification system for appraising deliveries at a tertiary referral hospital in Brazil.

Authors:  Elton C Ferreira; Rodolfo C Pacagnella; Maria L Costa; Jose G Cecatti
Journal:  Int J Gynaecol Obstet       Date:  2015-02-10       Impact factor: 3.561

6.  The pituitary gland in pregnancy: a clinicopathologic and immunohistochemical study of 69 cases.

Authors:  B W Scheithauer; T Sano; K T Kovacs; W F Young; N Ryan; R V Randall
Journal:  Mayo Clin Proc       Date:  1990-04       Impact factor: 7.616

7.  Isolated prolactin deficiency associated with serum autoantibodies against prolactin-secreting cells.

Authors:  Shintaro Iwama; Corrine K Welt; Christopher J Romero; Sally Radovick; Patrizio Caturegli
Journal:  J Clin Endocrinol Metab       Date:  2013-08-12       Impact factor: 5.958

8.  Incidence of early loss of pregnancy.

Authors:  A J Wilcox; C R Weinberg; J F O'Connor; D D Baird; J P Schlatterer; R E Canfield; E G Armstrong; B C Nisula
Journal:  N Engl J Med       Date:  1988-07-28       Impact factor: 91.245

9.  Robson 10-groups classification system to access C-section in two public hospitals of the Federal District/Brazil.

Authors:  Cláudia Vicari Bolognani; Lílian Barros de Sousa Moreira Reis; Adriano Dias; Iracema de Mattos Paranhos Calderon
Journal:  PLoS One       Date:  2018-02-20       Impact factor: 3.240

10.  The Increasing Trend in Caesarean Section Rates: Global, Regional and National Estimates: 1990-2014.

Authors:  Ana Pilar Betrán; Jianfeng Ye; Anne-Beth Moller; Jun Zhang; A Metin Gülmezoglu; Maria Regina Torloni
Journal:  PLoS One       Date:  2016-02-05       Impact factor: 3.240

View more
  4 in total

1.  Diagnosis and management of prolactinomas: current challenges.

Authors:  Stephan Petersenn; Andrea Giustina
Journal:  Pituitary       Date:  2020-02       Impact factor: 4.107

2.  Relationship between Blood and Standard Biochemistry Levels with Periodontitis in Parkinson's Disease Patients: Data from the NHANES 2011-2012.

Authors:  João Botelho; Patrícia Lyra; Luís Proença; Catarina Godinho; José João Mendes; Vanessa Machado
Journal:  J Pers Med       Date:  2020-07-25

3.  Italian Association of Clinical Endocrinologists (AME) and International Chapter of Clinical Endocrinology (ICCE). Position statement for clinical practice: prolactin-secreting tumors.

Authors:  Renato Cozzi; Maria Rosaria Ambrosio; Roberto Attanasio; Claudia Battista; Alessandro Bozzao; Marco Caputo; Enrica Ciccarelli; Laura De Marinis; Ernesto De Menis; Marco Faustini Fustini; Franco Grimaldi; Andrea Lania; Giovanni Lasio; Francesco Logoluso; Marco Losa; Pietro Maffei; Davide Milani; Maurizio Poggi; Michele Zini; Laurence Katznelson; Anton Luger; Catalina Poiana
Journal:  Eur J Endocrinol       Date:  2022-02-03       Impact factor: 6.664

4.  Self-reported periodontitis and C-reactive protein in Parkinson's disease: a cross-sectional study of two American cohorts.

Authors:  Patrícia Lyra; João Botelho; Vanessa Machado; Silvia Rota; Ryan Walker; Juliet Staunton; Luís Proença; Kallol Ray Chaudhuri; José João Mendes
Journal:  NPJ Parkinsons Dis       Date:  2022-04-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.